会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE
    • 乳腺癌相关疾病的治疗
    • US20100150882A1
    • 2010-06-17
    • US12706510
    • 2010-02-16
    • Jun TanPaul Sanberg
    • Jun TanPaul Sanberg
    • A61K35/14A61K35/16A61P25/28A61P3/10A61P7/00
    • A61K35/16A61K35/44A61K2035/122
    • Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
    • 使用人脐带血细胞(HUCBC)或HUCBC衍生血浆来治疗淀粉样蛋白病,如阿尔茨海默氏病,亨廷顿舞蹈病,脑淀粉样蛋白病和II型糖尿病。 通过输注HUCBC调节炎症反应导致淀粉样蛋白斑块和免疫相关细胞损伤的显着减少。 HUCBC输注也显着降低了小鼠模型中的脑淀粉样血管病变。 这些作用与CD40-CD40L相互作用的抑制有关,并且在免疫细胞上观察到表达CD-40的表达减少。 此外,A&bgr 吞噬活性增加,可溶性和不溶性A&bgr; 蛋白质水平通过治疗调节。 HUCBC输注的血清也显着增加了Aβ1-42肽的吞噬作用,抑制了免疫细胞CD40的表达,降低了脑淀粉样血管病变。
    • 10. 发明授权
    • HUCBC treatment of amyloid associated disease
    • HUCBC治疗淀粉样蛋白相关疾病
    • US09402870B2
    • 2016-08-02
    • US12706510
    • 2010-02-16
    • Jun TanPaul Sanberg
    • Jun TanPaul Sanberg
    • A61K35/12A61K35/16A61K35/44
    • A61K35/16A61K35/44A61K2035/122
    • Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
    • 使用人脐带血细胞(HUCBC)或HUCBC衍生血浆来治疗淀粉样蛋白病,如阿尔茨海默氏病,亨廷顿舞蹈病,脑淀粉样蛋白病防治病和II型糖尿病。 通过输注HUCBC调节炎症反应导致淀粉样蛋白斑块和免疫相关细胞损伤的显着减少。 HUCBC输注也显着降低了小鼠模型中的脑淀粉样血管病变。 这些作用与CD40-CD40L相互作用的抑制有关,并且在免疫细胞上观察到表达CD-40的表达减少。 此外,Aβ吞噬活性增加,可溶性和不溶性Aβ蛋白水平通过治疗调节。 HUCBC输注的血清也显着增加了Aβ1-42肽的吞噬作用,抑制了免疫细胞CD40表达,降低了脑淀粉样血管病变。